ClinicalTrials.gg
CompletedNCT04372186EMPACTAUpdated Feb 10, 2023Results posted

A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia

A Phase 3 interventional study of Placebo and Tocilizumab in COVID-19 Pneumonia, sponsored by Genentech, Inc.. Completed at 44 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-10.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
377
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing tocilizumab in COVID-19 — 3 open to participants now, 4 under way, 2 of them phase 3. tocilizumab · COVID-19.

Enrollment
9th of 38
377 · median 150
Started
2020
with 33 others
Phase 3
13 of 38
2 open now
Registered
18th of 38
by date

Among the 38 studies testing tocilizumab in COVID-19, this one is the 9th largest by enrollment, is one of 34 that started in 2020, is one of 13 in phase 3, and was the 18th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 38 studies testing tocilizumab in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing tocilizumab in COVID-19, or all of them as a file.
02

Study summary

This study (EMPACTA) will a) evaluate the efficacy and safety of tocilizumab (TCZ) compared with a placebo in combination with standard of care (SOC) in hospitalized participants with COVID-19 pneumonia, and b) include an optional long-term extension for eligible participants to explore the long-term sequelae of resolved COVID-19 pneumonia.

03

Conditions studied

  • COVID-19 Pneumonia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalized
  • COVID-19 pneumonia confirmed by a positive polymerase chain reaction (PCR) of any specimen and radiographic imaging
  • SpO2 \< 94% while on ambient air

Inclusion Criteria Specific to Long-Term Extension

  • Participated in Study ML42528 (EMPACTA) (includes participants who completed or discontinued early from the main study)

Exclusion criteria

Exclusion Criteria

  • Known severe allergic reactions to TCZ or other monoclonal antibodies
  • Require continuous positive airway pressure (CPAP), bilevel positive airway pressure (BIPAP), or invasive mechanical ventilation
  • Suspected active bacterial, fungal, viral, or other infection (besides COVID-19)
  • In the opinion of the investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments
  • (besides well-controlled ) or on immunosuppressive therapy (except for for COVID), advanced cancer
  • Have received oral anti-rejection or immunomodulatory drugs (including TCZ) within the past 3 months
  • Participating in another interleukin (IL)-6 antagonist clinical trial or other drug clinical trials (participation in COVID-19 anti-viral trials may be permitted if approved by Medical Monitor)
  • (ALT) or aspartate aminotransferase (AST) > 10 x (ULN) detected within 24 hours at screening (according to local laboratory reference ranges)
  • (ANC) \< 1000/uL at screening (according to local laboratory reference ranges)
  • count \< 50,000/uL at screening (according to local laboratory reference ranges)
  • Pregnant or breastfeeding, or positive pregnancy test in a pre-dose examination
  • Treatment with an drug within 5 half lives or 30 days (whichever is longer) of randomization (investigational COVID-19 antivirals may be permitted if approved by Medical Monitor)
  • Any serious medical condition or abnormality of clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study
  • Any history of Diverticulitis or GI perforation
  • Use of systemic corticosteroids unless on a stable chronic dose
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
377 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants will receive one intravenous (IV) infusion of placebo, in addition to SOC. Up to one additional infusion may be given.

    Drug: Placebo

  • Experimental
    Tocilizumab

    Participants will receive one IV infusion of TCZ in addition to SOC. Up to one additional infusion may be given.

    Drug: Tocilizumab

Interventions

  • DrugPlacebo

    Participants will receive one dose of IV placebo matched to TCZ. Up to one additional dose may be given.

  • Participants will receive one IV infusion of TCZ 8 mg/kg, with a maximum dose of 800 mg. Up to one additional dose may be given.

06

What researchers measure

Primary outcomes

  1. Cumulative Proportion of Participants Who Died or Required Mechanical Ventilation by Day 28

    Cumulative proportion is measured as a percentage of participants meeting the endpoint.

    Time frame: Up to Day 28

Secondary outcomes

  1. Time to Hospital Discharge or "Ready for Discharge" (as Evidenced by Normal Body Temperature and Respiratory Rate, and Stable Oxygen Saturation on Ambient Air or >/= 2 Liters (L) Supplemental Oxygen)

    Time frame: Up to Day 28

  2. Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status

    Clinical status was assessed using a 7-category ordinal scale: 1. - Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or \</=2 liters supplemental oxygen) 2. - Non- intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. - Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. - ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. - ICU, requiring intubation and mechanical ventilation 6. - ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support 7. - Death

    Time frame: Up to Day 28

  3. Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (Whichever Occurred First)

    Time frame: Up to Day 28

  4. Mortality Rate by Day 28

    Time frame: Up to Day 28

  5. Clinical Status on 7-Category Ordinal Scale at Day 28

    Clinical status was assessed using a 7-category ordinal scale: 1. - Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or \</=2 liters supplemental oxygen) 2. - Non- intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. - Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. - ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. - ICU, requiring intubation and mechanical ventilation 6. - ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support 7. - Death

    Time frame: Day 28

  6. Percentage of Participants With Adverse Events

    Time frame: Up to Day 60

07

Results

Posted Sep 27, 2021

Participant flow

Participant flow — Overall Study
MilestoneTocilizumabPlacebo
Started249128
Completed225115
Not completed2413
Withdrew: Death2411
Withdrew: Transferred to a different facility for care02

Outcome measures

PrimaryCumulative Proportion of Participants Who Died or Required Mechanical Ventilation by Day 28

Cumulative proportion is measured as a percentage of participants meeting the endpoint.

Time frame:
Up to Day 28
Reported as:
Number · Percentage of Participants
Cumulative Proportion of Participants Who Died or Required Mechanical Ventilation by Day 28
Percentage of ParticipantsTocilizumabPlacebo
Cumulative Proportion of Participants Who Died or Required Mechanical Ventilation by Day 2812.04 (8.52 to 16.86)19.26 (13.34 to 27.36)
SecondaryTime to Hospital Discharge or "Ready for Discharge" (as Evidenced by Normal Body Temperature and Respiratory Rate, and Stable Oxygen Saturation on Ambient Air or >/= 2 Liters (L) Supplemental Oxygen)
Time frame:
Up to Day 28
Reported as:
Median · Days
Time to Hospital Discharge or "Ready for Discharge" (as Evidenced by Normal Body Temperature and Respiratory Rate, and Stable Oxygen Saturation on Ambient Air or >/= 2 Liters (L) Supplemental Oxygen)
DaysTocilizumabPlacebo
Time to Hospital Discharge or "Ready for Discharge" (as Evidenced by Normal Body Temperature and Respiratory Rate, and Stable Oxygen Saturation on Ambient Air or >/= 2 Liters (L) Supplemental Oxygen)6.0 (6.0 to 7.0)7.5 (7.0 to 9.0)
SecondaryTime to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status

Clinical status was assessed using a 7-category ordinal scale: 1. - Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or \</=2 liters supplemental oxygen) 2. - Non- intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. - Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. - ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. - ICU, requiring intubation and mechanical ventilation 6. - ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support 7. - Death

Time frame:
Up to Day 28
Reported as:
Median · Days
Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status
DaysTocilizumabPlacebo
Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status6.0 (6.0 to 7.0)7.0 (6.0 to 9.0)
SecondaryTime to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (Whichever Occurred First)
Time frame:
Up to Day 28
Reported as:
Median · Days
Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (Whichever Occurred First)
DaysTocilizumabPlacebo
Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (Whichever Occurred First)NA (NA to NA)NA (NA to NA)
SecondaryMortality Rate by Day 28
Time frame:
Up to Day 28
Reported as:
Number · Percentage of Participants
Mortality Rate by Day 28
Percentage of ParticipantsTocilizumabPlacebo
Mortality Rate by Day 2810.4 (7.2 to 14.9)8.6 (4.9 to 14.7)
SecondaryClinical Status on 7-Category Ordinal Scale at Day 28

Clinical status was assessed using a 7-category ordinal scale: 1. - Discharged (or "ready for discharge" as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or \</=2 liters supplemental oxygen) 2. - Non- intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. - Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. - ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. - ICU, requiring intubation and mechanical ventilation 6. - ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support 7. - Death

Time frame:
Day 28
Reported as:
Number · Percentage of participants
Clinical Status on 7-Category Ordinal Scale at Day 28
Percentage of participantsTocilizumabPlacebo
185.982.8
20.41.6
32.00.8
40.40.8
50.83.9
601.6
710.48.6
SecondaryPercentage of Participants With Adverse Events
Time frame:
Up to Day 60
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events
Percentage of participantsTocilizumabPlacebo
Percentage of Participants With Adverse Events50.852.8

Adverse events

Collected over Up to Day 60. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tocilizumab29/250 (11.6%)38/250 (15.2%)28/250 (11.2%)
Placebo15/127 (11.8%)25/127 (19.7%)8/127 (6.3%)
Most frequent serious events
Showing 10 of 54
Most frequent serious events
EventTocilizumabPlacebo
COVID-19 pneumoniaInfections and infestations2/2503/127
PneumoniaInfections and infestations0/2503/127
Septic shockInfections and infestations5/2503/127
Acute kidney injuryRenal and urinary disorders1/2503/127
Acute respiratory failureRespiratory, thoracic and mediastinal disorders4/2503/127
Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders5/2501/127
Respiratory failureRespiratory, thoracic and mediastinal disorders4/2502/127
Pneumonia bacterialInfections and infestations0/2502/127
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/2501/127
Cardiac arrestCardiac disorders2/2501/127
Most frequent other events
Most frequent other events
EventTocilizumabPlacebo
ConstipationGastrointestinal disorders16/2504/127
AnxietyPsychiatric disorders15/2504/127

Baseline characteristics

mITT population = all randomized participants who received study treatment, grouped according to the treatment assigned at randomization. Participants not receiving study treatment were excluded from analyses.

Age, Continuous
Age, Continuous(Years)TocilizumabPlaceboTotal
Mean56.0 ± 14.355.6 ± 14.955.9 ± 14.4
Sex: Female, Male
Sex: Female, Male(Participants)TocilizumabPlaceboTotal
Female9955154
Male15073223
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TocilizumabPlaceboTotal
Hispanic or Latino14368211
Not Hispanic or Latino10660166
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TocilizumabPlaceboTotal
American Indian or Alaska Native522577
Asian516
Native Hawaiian or Other Pacific Islander011
Black or African American352257
White13465199
More than one race426
Unknown or Not Reported191231
08

Study locations

44 sites
  • Banner - University Medical Center Phoenix; In-Patient Pharmacy
    Phoenix, Arizona 85006, United States
  • Univ of AZ Coll of Med
    Tucson, Arizona 85724, United States
  • El Centro Regional Medical Center
    El Centro, California 92243, United States
  • eStudySite
    La Mesa, California 91942, United States
  • Highland Hospital Oakland
    Oakland, California 94602, United States
  • St. Joseph'S Hospital
    Orange, California 92563, United States
  • San Leandro Hospital; Inpatient Pharmacy
    San Leandro, California 94578, United States
  • Larkin Community Hospital Palm Springs Campus (Hialeah)
    Hialeah, Florida 33012, United States
  • Miami Veterans Administration Healthcare System - NAVREF
    Miami, Florida 33125, United States
  • University of Miami Pulmonary
    Miami, Florida 33125, United States
  • Larkin Community Hospital
    South Miami, Florida 33143, United States
  • St. Lukes Boise Medical Center
    Boise, Idaho 83712, United States
  • Ochsner Clinic
    New Orleans, Louisiana 70121, United States
  • Holy Cross Germantown Hospital
    Germantown, Maryland 20876, United States
  • Holy Cross Hospital
    Silver Spring, Maryland 20910, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • St. Joseph'S Regional Medical Center
    Paterson, New Jersey 07503, United States
  • San Juan Oncology Associates
    Farmington, New Mexico 87401, United States
  • St. Barnabas Hospital
    Bronx, New York 10457, United States
  • SUNY Downstate Medical Center.
    Brooklyn, New York 11203, United States
  • Elmhurst Hospital Center
    Elmhurst, New York 11373, United States
  • Flushing Hospital
    Flushing, New York 11355, United States
  • Jamaica Hospital Medical Center
    Jamaica, New York 11418, United States
  • Harlem Hospital
    New York, New York 10037, United States
  • Canton-Potsdam Hospital
    Potsdam, New York 13676, United States
  • Novant Health Presbyterian Medical Center (Presbyterian Hospital)
    Charlotte, North Carolina 28204, United States
  • Cape Fear Valley Medical Center
    Fayetteville, North Carolina 28304, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • Valley Baptist Medical Center
    Harlingen, Texas 78550, United States
  • Michael E Debakey VA Medical Center
    Houston, Texas 77030, United States
  • McAllen Medical Center
    McAllen, Texas 78503, United States
  • Sentara Medical Group
    Virginia Beach, Virginia 23462, United States
  • Hospital E Maternidade Celso Pierro PUCCAMP
    Campinas, SP 13060-904, Brazil
  • Centro Multidisciplinar de Estudos Clínicos CEMEC FMABC
    Sao Bernardo Do Campo, SP 09715-090, Brazil
  • BR Trials - Pesquisa Clínica
    Sao Paulo, SP 03325-050, Brazil
  • Aga Khan University Hospital
    Nairobi, 30270-00100, Kenya
  • Hospital General de Culiacan
    Culiacan, 80230, Mexico
  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
    Mexico, Mexico
  • Hospital Militar Central
    Jesus Maria, Lima 11, Peru
  • Hospital Nacional Sergio E. Bernales
    Lima, 15003, Peru
  • Hospital Nacional Cayetano Heredia
    Lima, 31, Peru
  • Hospital Nacional Hipolito; Unanue
    Lima, Lima 10, Peru
  • Hospital Maria Auxiliadora
    Lima, Lima 29, Peru
  • George Provincial Hospital
    George, 6259, South Africa
09

References and documents

Publications

  • Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, Criner GJ, Kaplan-Lewis E, Baden R, Pandit L, Cameron ML, Garcia-Diaz J, Chavez V, Mekebeb-Reuter M, Lima de Menezes F, Shah R, Gonzalez-Lara MF, Assman B, Freedman J, Mohan SV. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021 Jan 7;384(1):20-30. doi: 10.1056/NEJMoa2030340. Epub 2020 Dec 17. PubMed 33332779 ↗
  • Tleyjeh IM. The Misleading "Pooled Effect Estimate" of Crude Data from Observational Studies at Critical Risk of Bias: The Case of Tocilizumab in Coronavirus Disease 2019 (COVID-19). Clin Infect Dis. 2021 Jun 15;72(12):e1154-e1155. doi: 10.1093/cid/ciaa1735. No abstract available. PubMed 33201228 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Aug 2020, 3 months.

Results were first posted in Sep 2021, 1 year 1 month after primary completion.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 3 months is below that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2020
First posted
May 1, 2020
StartActual
May 14, 2020
Primary completionActual
Aug 18, 2020
CompletionActual
Sep 22, 2020
Results first posted
Sep 27, 2021
Last update
Feb 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04372186
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
May 1, 2020
Start date
May 14, 2020
Primary completion
Aug 18, 2020
Completion
Sep 22, 2020
Results posted
Sep 27, 2021
Last update
Feb 10, 2023

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion